Compare iShares MSCI Hong Kong ETF (EWH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares MSCI Hong Kong ETF trades at $22.09 (market cap $1.16B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 8.7× iShares MSCI Hong Kong ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Hong Kong ETF for 61 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| EWH | XBI | |
|---|---|---|
Market Cap | $1.16B | $10.11B |
Volume | 3,176,523 | 12,903,266 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $24.55 | $169.55 |
52-Week Low | $20.66 | $104.99 |
Typical Hold Time | 61 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.06 with a 2.22% daily gain but maintains a bearish technical outlook. The ETF tracks Hong Kong equities, which face headwinds from Federal Reserve policy and US-Iran tensions, as the Hang Seng Index has declined over 11% from yearly highs. Moving averages signal strong bearish momentum while oscillators show neutral conditions, with key support at $21.
The outlook remains cautious given Hong Kong's sensitivity to US-China relations and Fed policy. Near-term performance hinges on geopolitical developments and Chinese economic data. Risks include continued institutional selling and Hang Seng volatility, but oversold conditions may attract contrarian buyers if tensions ease.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
